CalliSpheres载药微球用于经支气管动脉化疗栓塞治疗晚期非小细胞肺癌  

Trans-bronchial artery chemoembolization using CalliSpheres drug-eluting beads for advanced non-small cell lung cancer

作　　者：周士朝 杜晶磊 王焱 贾藩 薛文强 樊江波 于世平[2] ZHOU Shizhao;DU Jinglei;WANG Yan;JIA Fan;XUE Wenqiang;FAN Jiangbo;YU Shiping(Institute of Medical Imaging,Shanxi Medical University,Taiyuan 030001,China;Department of Intervention Therapy,Second Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学医学影像学院,山西太原030001 [2]山西医科大学第二医院介入治疗科,山西太原030001

出　　处：《中国介入影像与治疗学》2022年第12期761-765,共5页Chinese Journal of Interventional Imaging and Therapy

基　　金：山西医科大学第二医院青年基金项目(202202-1)。

摘　　要：目的观察以载药微球(DEB)CalliSpheres行经支气管动脉化疗栓塞(BACE)治疗晚期非小细胞肺癌(NSCLC)的效果及安全性。方法回顾性分析26例接受以CalliSpheres行DEB-BACE的晚期NSCLC患者;术后1、3个月复查胸部CT,以改良实体瘤疗效评价标准(mRECIST)评价疗效,观察不良反应,统计疾病无进展生存期(PFS)及总生存期(OS)。结果26例均成功接受DEB-BACE。术后1个月客观缓解率(ORR)为73.08%(19/26),疾病控制率(DCR)为96.15%(25/26);术后3个月ORR为57.69%(15/26),DCR为92.31%(24/26)。不良反应包括恶心(18例)、呕吐(12例)等,均为1、2级,经对症治疗后均好转。术后随访3~31(16.79±7.36)个月,患者3、6、12及24个月生存率分别为100%、100%、100%及84.62%(22/26),中位PFS为9(3~18)个月,中位OS为17(3~31)个月。结论CalliSpheres用于DEB-BACE治疗晚期NSCLC安全、有效。Objective To observe the efficacy and safety of trans-bronchial artery chemoembolization(DEB-BACE)using CalliSpheres drug eluting beads for treating advanced non-small cell lung cancer(NSCLC).Methods Data of 26 patients with advanced NSCLC who received DEB-BACE using CalliSpheres were retrospectively analyzed.Thoracic CT was reexamined 1 and 3 months after DEB-BACE,and the efficacy and safety of DEB-BACE using CalliSpheres were evaluated according to the modified response evaluation criteria in solid tumors(mRECIST).Adverse reactions were observed,and progression-free survival(PFS)and overall survival(OS)were counted.Results All 26 patients were successfully treated with DEB-BACE.The objective response rate(ORR)and disease control rate(DCR)was 73.08%(19/26)and 96.15%(25/26)1 month after treatment,while 57.69%(15/26)and 92.31%(24/26)3 months after treatment,respectively.The follow-up period time was 3-31(16.79±7.36)months,and the 3-,6-,12-and 24-month survival rates was 100%,100%,100%and 84.62%(22/26),respectively.The median PFS(mPFS)was 9 months(3-18 months),and the median OS(mOS)was 17 months(3-31 months).The adverse reactions included postoperative nausea(n=18)and vomiting(n=12),etc.,all were grade 1 and 2 and improved after symptomatic treatment.Conclusion DEB-BACE using CalliSpheres was safe and effective for treating advanced NSCLC.

关 键 词：癌 非小细胞肺 栓塞 治疗性 CalliSpheres载药微球 

分 类 号：R734.2[医药卫生—肿瘤] R815[医药卫生—临床医学]